TransMedics EV/EBIT TMDX
Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2024.
- Today, Nov 2, 2026
- 32.9×
- 2-year median
- 49.3×
- Against its 2-year history
- 16th
- percentile: 0 is its lowest day, 100 its highest
- 2-year range
- 27.2× to 98.5×
- Peer median
- 21.8×
TransMedics' EV/EBIT is 32.9× as of Nov 2, 2026.
That is below its 2-year median of 49.3×, lower than on 84% of days in the last 2 years.
Over that time it ranged from 27.2× in May 2026 to 98.5× in Nov 2024.
The median for 4 medical device stocks of a similar size is 21.8×.
EV/EBIT over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 32.9× | 27.2× | 51.6× |
| 2025 | 44.8× | 41.5× | 96.0× |
| 2024 | 71.1× | 71.1× | 98.5× |
Against its peers
Companies in Medical - Devices nearest TransMedics' size, closest first, today.
| Company | EV/EBIT |
|---|---|
| TMDXTransMedics | 32.9× |
| CNMDCONMED | 19.8× |
| ITGRInteger | 29.7× |
| LIVNLivaNova | 22.4× |
| ZBHZimmer Biomet | 21.3× |
| Peer median | 21.8× |
Where TransMedics ranks
What the EV/EBIT tells you
What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.
Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.
More on TransMedics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.